A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Our Company We are a commercial-stage biopharmaceutical company advancing innovative cancer therapies. We currently have two commercially approved medicines, Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr), and a robust slate of clinical development programs designed to unlock the full potential of our first two products. Revuforj is our first-in-class menin inhibitor that was approved by the U.S. Food and Drug Administration, or FDA, in November 2024 for the treatment of relapsed or refractory, or R/R, acute leukemia with a lysine methyltransferase 2A gene, or KMT2A, translocation in adult and pediatric patients one year old and older. In October 2025, Revuforj received a second approval from the FDA for the treatment of R/R acute myeloid leukemia, or AML, with a susceptible nucleophosmin 1 mutation, or NPM1m, in adult and pediatric patients one year and older who have no satisfactory alternative treatment options.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 172M | 172M | - | 0 | 0 | 140M |
| Net Income | -285M | -285M | -319M | -209M | -149M | 25M |
| EPS | $-3.29 | $-3.29 | $-3.72 | $-2.98 | $-2.46 | $0.46 |
| Free Cash Flow | -323M | -323M | -275M | -161M | -134M | 29M |
| ROIC | -77.1% | -1049.3% | -411.3% | -37.8% | -31.9% | 6.4% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 5.42 | 5.42 | 1.21 | 0.00 | 0.06 | 0.05 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -273M | -273M | -340M | -230M | -152M | 26M |
| Operating Margin | -158.4% | -158.4% | - | - | - | 18.8% |
| ROE | -441.6% | -161.8% | -110.6% | -37.8% | -31.9% | 6.1% |
| Shares Outstanding | 87M | 87M | 86M | 70M | 61M | 0M |
Syndax Pharmaceuticals Inc passes 0 of 9 quality checks, indicating weak fundamentals.
Syndax Pharmaceuticals Inc (SNDX) has a 5-year average return on invested capital (ROIC) of -21.1%. This is below average and may indicate limited pricing power.
Syndax Pharmaceuticals Inc (SNDX) has a market capitalization of $2.1B. It is classified as a mid-cap stock.
Syndax Pharmaceuticals Inc (SNDX) does not currently pay a regular dividend.
Syndax Pharmaceuticals Inc (SNDX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Syndax Pharmaceuticals Inc (SNDX) reported annual revenue of $172 million in its most recent fiscal year, based on SEC EDGAR filings.
Syndax Pharmaceuticals Inc (SNDX) has a net profit margin of -165.6%. The company is currently unprofitable.
Syndax Pharmaceuticals Inc (SNDX) generated $-323 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Syndax Pharmaceuticals Inc (SNDX) has a debt-to-equity ratio of 5.42. This indicates higher leverage, which may increase financial risk.
Syndax Pharmaceuticals Inc (SNDX) reported earnings per share (EPS) of $-3.29 in its most recent fiscal year.
Syndax Pharmaceuticals Inc (SNDX) has a return on equity (ROE) of -161.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 11 years of financial data for Syndax Pharmaceuticals Inc (SNDX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Syndax Pharmaceuticals Inc (SNDX) has a book value per share of $0.74, based on its most recent annual SEC filing.